Immuron CEO, Steven Lydeamore Investor Webinar Presentation
28 nov. 2023 06h33 HE
|
Immuron Limited
MELBOURNE, Australia, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to invite...
Immuron CEO Steven Lydeamore Investor Webinar Presentation
13 nov. 2023 18h00 HE
|
Immuron Limited
MELBOURNE, Australia, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to invite...
Immuron CEO Steven Lydeamore presented at AusBioInvest
30 oct. 2023 07h21 HE
|
Immuron Limited
MELBOURNE, Australia, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company, is pleased to advise our...
Immuron Announces Travelan® Clinical Study Cohort 2 commences
18 oct. 2023 06h00 HE
|
Immuron Limited
Highlights: Second cohort of 34 healthy volunteers enrolled in the Travelan® Clinical Trial Clinical Trial to examine a dosing regimen for Travelan® more suited to the US military has commenced...
Immuron achieves record quarterly Travelan® sales
11 oct. 2023 06h00 HE
|
Immuron Limited
Highlights: Record quarterly Travelan® sales of $1,550,240Total sales of A$1,565,767 in Q1, FY24 $1,508,933 increase on Q1, FY23 sales130% higher than pre-pandemic period Q1, FY20 sales ...
Immuron achieves record monthly Travelan® sales
13 sept. 2023 06h00 HE
|
Immuron Limited
Highlights: Record monthly Travelan® salesAustralian sales of A$1.18 M in August 2023 (7984% increase on August 2022 sales) MELBOURNE, Australia, Sept. 13, 2023 (GLOBE NEWSWIRE) -- Immuron...
Immuron CEO, Steven Lydeamore to present at H.C. Wainwright
11 sept. 2023 06h00 HE
|
Immuron Limited
MELBOURNE, Australia, Sept. 11, 2023 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to advise our...
Immuron to present at the Military Health System Research Symposium
14 août 2023 06h00 HE
|
Immuron Limited
MELBOURNE, Australia, Aug. 14, 2023 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to announce that it...
Immuron Announces First Patients Enrolled in Travelan® Clinical Study
25 juil. 2023 06h00 HE
|
Immuron Limited
Highlights: First cohort of 30 healthy volunteers enrolled in the Travelan® Clinical Trial Clinical Trial to examine a dosing regimen for Travelan® more suited to the US military has commenced...
Immuron CEO, Steven Lydeamore to present at Bioshares
24 juil. 2023 06h00 HE
|
Immuron Limited
MELBOURNE, Australia, July 24, 2023 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to advise our Chief...